Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. Choi BS, et al. Among authors: holen kd. Cancer Chemother Pharmacol. 2010 Oct;66(5):973-80. doi: 10.1007/s00280-010-1250-z. Epub 2010 Feb 2. Cancer Chemother Pharmacol. 2010. PMID: 20127092 Free PMC article. Clinical Trial.
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. Schelman WR, et al. Among authors: holen kd. Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10. Invest New Drugs. 2013. PMID: 24114121 Free PMC article. Clinical Trial.
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G. LoConte NK, et al. Among authors: holen kd. Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17. Invest New Drugs. 2015. PMID: 25318436 Free PMC article. Clinical Trial.
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. Mulkerin D, et al. Among authors: holen kd. Invest New Drugs. 2009 Oct;27(5):461-8. doi: 10.1007/s10637-008-9210-8. Epub 2009 Jan 8. Invest New Drugs. 2009. PMID: 19129971 Free PMC article. Clinical Trial.
69 results